48
Participants
Start Date
July 7, 2020
Primary Completion Date
December 31, 2020
Study Completion Date
March 31, 2021
Irinotecan Liposome Injection combined with 5-FU/LV
Drug: Irinotecan Liposome Injection 70mg/m2 (CSPC) combined with 5-FU/LV; Drug: Irinotecan Liposome Injection 70mg/m2 (Ipsen, ONIVYDETM) combined with 5-FU/LV;
RECRUITING
Tianjin Cancer Hospital, Tianjin
Lead Sponsor
CSPC Ouyi Pharmaceutical Co., Ltd.
INDUSTRY